Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurotech International ( (AU:NTI) ) just unveiled an announcement.
Neurotech International Limited held its Annual General Meeting, where all resolutions were determined by a poll. The meeting’s outcomes, including the adoption of the remuneration report and re-election of Mark Davies, were carried successfully, indicating strong shareholder support. This meeting underscores Neurotech’s stable governance and continued focus on advancing its clinical programs, potentially enhancing its position in the biopharmaceutical industry.
More about Neurotech International
Neurotech International Limited is a clinical-stage biopharmaceutical development company focusing on pediatric neurological disorders. The company is developing a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has conducted successful Phase II/III clinical trials in Autism Spectrum Disorder (ASD) and Phase I/II trials in ASD, PANDAS/PANS, and Rett Syndrome, with plans for a trial in spastic cerebral palsy.
Average Trading Volume: 1,392,257
Technical Sentiment Signal: Sell
Current Market Cap: A$16.79M
For a thorough assessment of NTI stock, go to TipRanks’ Stock Analysis page.